Alignment Healthcare reported an internal transaction on February 10, 2026, in which Chief Human Resources Officer Andreas P. Wagner sold 22,238 shares of common stock at $20.47 per share, producing gross proceeds of $455,211.
Following that disposition, Wagner is recorded as directly holding 169,805 shares of Alignment Healthcare. Company filings state the sale was carried out to meet tax withholding obligations associated with vesting restricted share units and was not a discretionary trade by Wagner.
Alongside the insider transaction, Alignment Healthcare has outlined membership and financial guidance that has attracted attention from equity analysts. The company projects that its health plan membership will increase by 24-27% by the end of 2026, a range that would place membership between 290,000 and 296,000 members. That forecast follows an annual enrollment period that produced approximately 275,300 members as of January 1, representing a 31% year-over-year increase.
Analyst actions following the membership update include KeyBanc raising its price target for Alignment Healthcare to $28 while maintaining an Overweight rating, noting that the company’s EBITDA guidance is in line with the current consensus expectation of $145 million. Piper Sandler also lifted its price target to $30, explicitly citing strong sales and retention during the Annual Enrollment Period as drivers for the change. In a separate move, JPMorgan upgraded the stock from Neutral to Overweight and increased its price target to $20.
These corporate and analyst updates together present a mix of company-provided projections and third-party reassessments. The insider sale was executed for tax-related reasons tied to restricted share units and is described in filings as non-discretionary. The membership outlook and analyst adjustments remain forward-looking items presented by the company and investment banks.